A NOVEL MECHANISM OF ACTION

TROGARZO® (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor.1

TROGARZO® is a humanized monoclonal antibody that binds to domain 2 of CD4 on the surface of immune cells.

The HIV-1 envelope glycoprotein (gp120) binds to domain 1 of CD4. Through steric hindrance, TROGARZO® blocks the steps required for viral entry without interfering in normal CD4-mediated immune functions.

THE FIRST MONOCLONAL ANTIBODY FOR HIV-1, ACTIVE AGAINST STRAINS RESISTANT TO ALL APPROVED ANTIRETROVIRALS.

Is Trogarzo® Right For Your Patients?

ACTIVITY AMONG CLASSES

Activity Among Classes
  • TROGARZO® is active against HIV-1 strains resistant to all approved antiretrovirals.
  • There is no evidence of cross-resistance between TROGARZO® and any of the approved classes of antiretrovirals (NRTI, NNRTI, PI, INSTI, CCR5 antagonist, fusion inhibitor).

HIV-1 TROPISM

HIV-1 Tropism
  • TROGARZO® activity is independent of co-receptor tropism (CXCR4 vs. CCR5).
EXPLORE DOSING AND ADMINISTRATION

CCR5 = C-C chemokine receptor type 5; CXCR4 = C-X-C chemokine receptor type 4; INSTI = Integrase Strand Transfer Inhibitor;
NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor; NRTI = Nucleoside Reverse Transcriptase Inhibitor; PI = Protease Inhibitor